Find in Library

Cost-consequence analysis (CCA) of sacubitril/valsartan versus angiotensin converting enzyme inhibitors (ACEi) in chronic heart failure patients with reduced ejection fraction (HFrEF) in Indian healthcare setting

oleh: Sameee Bhasker Gokale, Gauri Billa, Sushant Anand, Sanchit Nanda